• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Stevanato Group S.p.A.

    3/6/25 4:00:03 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care
    Get the next $STVN alert in real time by email
    6-K 1 6-k_press_release_mar_6_.htm 6-K 6-K

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of March 2025

    Commission File Number: 001-40618

    Stevanato Group S.p.A.

    (Translation of registrant’s name into English)

    Via Molinella 17

    35017 Piombino Dese – Padua

    Italy

    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40‑F.

    Form 20-F ☒ Form 40-F ☐

     

     

     


     

     

    EXHIBIT INDEX

     

    The following exhibits are furnished as part of this Form 6-K:

     

    Exhibit

    Description

    99.1

    Press release dated March 6, 2025

     

     

     

     

     

     


     

     

     

     

     

     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    Stevanato Group S.p.A.

    Date: March 6, 2025

    By:

    /s/ Franco Stevanato

    Name:

    Franco Stevanato

    Title:

    Chief Executive Officer

     

     

     

     

     

     

     

     

     


    Get the next $STVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STVN

    DatePrice TargetRatingAnalyst
    12/2/2025$24.00Equal-Weight
    Morgan Stanley
    12/13/2024$28.00Outperform
    Wolfe Research
    12/3/2024$23.00Equal-Weight
    Morgan Stanley
    4/22/2024Outperform
    Exane BNP Paribas
    11/1/2023$39.00 → $29.00Buy → Hold
    Jefferies
    9/26/2023$33.00Overweight
    Stephens
    9/19/2023Market Outperform
    CJS Securities
    8/24/2023$34.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $STVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025

    Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025. Third Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 9% (11% on a constant currency basis) to €303.2 million. High-value solutions represented a record 49% of total revenue. Gross profit margin increased 240 basis points to 29.2%. Diluted earnings per share were

    11/6/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group to Participate in Upcoming Investor Conferences

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in two upcoming investor conferences. Monday, November 17, 2025, at 8:40 a.m. ET - The 7th Annual Wolfe Research Healthcare Conference in New York City Wednesday, November 19, 2025, at 11:00 a.m. GMT - The Jefferies Global Healthcare Conference in London A live webcast of each event will be available on the Company's website at www.stevanatogroup.com under the "Investors" section. Replays will remain available for approximately 90 days after each event.

    10/31/25 7:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, November 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pr

    10/22/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Stevanato Group S.p.A. with a new price target

    Morgan Stanley resumed coverage of Stevanato Group S.p.A. with a rating of Equal-Weight and set a new price target of $24.00

    12/2/25 8:34:50 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Wolfe Research initiated coverage on Stevanato Group S.p.A. with a new price target

    Wolfe Research initiated coverage of Stevanato Group S.p.A. with a rating of Outperform and set a new price target of $28.00

    12/13/24 8:24:13 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Morgan Stanley resumed coverage on Stevanato Group S.p.A. with a new price target

    Morgan Stanley resumed coverage of Stevanato Group S.p.A. with a rating of Equal-Weight and set a new price target of $23.00

    12/3/24 8:38:45 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Stevanato Group S.p.A.

    SCHEDULE 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    12/3/25 2:38:08 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Stevanato Group S.p.A.

    6-K - Stevanato Group S.p.A. (0001849853) (Filer)

    11/18/25 4:00:03 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Stevanato Group S.p.A.

    6-K - Stevanato Group S.p.A. (0001849853) (Filer)

    11/6/25 4:10:20 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Stevanato Group S.p.A.

    SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    11/14/24 4:06:28 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stevanato Group S.p.A.

    SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    11/14/24 3:30:56 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Stevanato Group S.p.A.

    SC 13G - Stevanato Group S.p.A. (0001849853) (Subject)

    11/14/24 1:28:35 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Leadership Updates

    Live Leadership Updates

    View All

    Stevanato Group Announces Results of Annual General Meeting

    -All Resolutions Proposed to Shareholders Passed- Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders ("AGM") held virtually on May 22, 2024, have passed. Details of the resolutions submitted to, and approved by, the AGM are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company's corporate website at https://ir.stevanatogroup.com/. Shareholders approved, among other things, th

    5/24/24 4:10:00 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group appoints Ugo Gay as Chief Operations Officer

    Strengthening corporate leadership aims to drive operational efficiencies and standardization of global processes. Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404727049/en/Ugo Gay appointed as Chief Operations Officer of Stevanato Group (Photo: Business Wire) The addition of Ugo Gay underscores Stevanato Group's unwavering commitment to driving opera

    4/4/24 8:00:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group Appoints Riccardo Butta as President, Americas

    The appointment bolsters company's commitment to growth in the region Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220202005514/en/Riccardo Butta (Photo: Business Wire) The appointment of a dedicated executive to lead the Company's long-term strategy in the Americas is indicative of the growing regional demand trends and the Company's commitment to broaden its footprint, accelerate i

    2/2/22 8:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Financials

    Live finance-specific insights

    View All

    Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025

    Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025. Third Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 9% (11% on a constant currency basis) to €303.2 million. High-value solutions represented a record 49% of total revenue. Gross profit margin increased 240 basis points to 29.2%. Diluted earnings per share were

    11/6/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, November 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pr

    10/22/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025

    Company delivers 8% revenue growth, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025. Second Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 8% to €280.0 million, and high-value solutions represented 42% of total revenue. Gross profit margin increased 210 basis points to 28.1%. Diluted earnings per share were €0.11; adjusted diluted earnings per share were €0.11. Adjusted EBITDA mar

    8/5/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care